Skip to main content

Attorney General Nessel Urges Consumers to Claim Compensation for Inflated Generic Drug Prices

LANSING – Michigan Attorney General Dana Nessel is urging consumers to check their eligibility for compensation for certain generic drug purchases and to submit a claim for compensation. The U.S. District Court for the District of Connecticut this month granted preliminary approval of a plan, filed by Michigan and a coalition of 47 other states and territories, to distribute settlement funds paid by generic drug manufacturers in exchange for settlement of claims that those companies illegally conspired to raise the prices of generic drugs. Consumers can file for compensation online.

The coalition previously announced settlements with drug manufacturers Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage’s parent company, Emcure, totaling approximately $96.5 million. The multistate coalition’s distribution plan aims to return millions of dollars from those settlement funds to those potentially harmed by the elevated prices of the generic drugs that are the subjects of those settlements.

“Consumers who paid the high price of generic drugs because companies placed profits over fairness are now entitled to compensation,” said Attorney General Nessel. “This settlement holds companies accountable for conspiring to inflate drug prices. If you purchased certain generic medications during the covered period, I encourage you to check your eligibility and file a claim. My office is committed to putting money back into the hands of those it belongs to: the consumers.”

If you purchased one of the generic drugs listed on the settlement website between May 2009 and December 2019, you may be eligible for compensation. To determine your eligibility, call 1-866-290-0182 (toll-free), email the settlement website (info@AGGenericDrugs.com), or visit the AG Generic Drugs website itself (www.AGGenericDrugs.com).

Michigan is part of a coalition of nearly all states and territories engaged in a series of antitrust cases, starting first in 2016. The first complaint included Heritage and 17 other corporate defendants, two individual defendants, and 15 generic drugs. The second complaint was filed in 2019 against Teva Pharmaceuticals and 21 of the nation’s largest generic drug manufacturers. The complaint names 16 individual senior executive defendants. The third complaint, to be tried first, focuses on 80 topical generic drugs that account for billions of dollars of sales in the United States. This complaint names 26 corporate defendants and 10 individual defendants. The States filed a fourth complaint in 2026 against Novartis AG, Sandoz Group AG and Sandoz AG. Seven pharmaceutical executives have been cooperating to support the States’ claims in these cases.

The above-mentioned cases stem from a series of investigations built on millions of documents, a massive phone record database, and evidence from several cooperating witnesses at the core of the different conspiracies. Each complaint addresses a different set of drugs and defendants and lays out an interconnected web of competing industry executives who regularly met and communicated with each other, providing ample opportunity to form illegal agreements. The complaints note that defendants used terms like “fair share,” “playing nice in the sandbox,” and “responsible competitor” to unlawfully discourage competition, raise prices, and enforce an ingrained culture of collusion.

Joining in the announcement were the states and territories of Alaska, Arizona, California, Colorado, Connecticut, Delaware, the District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Minnesota, Mississippi, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Northern Mariana Islands, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, U.S. Virgin Islands, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming.

###

Media Contact: